ArticleApplied microbiology and biotechnology2026
SphB1 export system for antigen presentation to the respiratory tract by a live pertussis vaccine.
Article in Applied microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BPZE1 is a live attenuated vaccine currently in advanced clinical development for nasal immunization against pertussis. The ability of this vaccine to induce mucosal and systemic, humoral and cellular immunity make it an attractive mucosal delivery system for heterologous antigens to induce immunity especially in the respiratory tract. Here, we have developed a heterologous antigen expression system based on the pertactin-deficient BPZE1 derivative IB-V002 by using the SphB1 secretion system to present the SARS-CoV-2 nucleocapsid protein (N) as a model antigen to the respiratory mucosa. SphB1 is an autotransporter comprising a subtilisin-like passenger domain and a C-terminal ß-barrel domain. The passenger domain was replaced by the SARS-CoV-2 N protein. The recombinant gene was inserted into the urease locus of IB-V002 and placed under the control of the pertactin promoter and signal peptide. Immunoblot analyses indicated that the chimeric protein was produced and secreted by the recombinant strain named BT-V101. Mice intranasally immunized with BT-V101 induced N-specific IgG in serum and IFN-γ production by spleen cells. Importantly, a local N-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.